Large neutral amino acid transporter enables brain drug delivery via prodrugs.
about
Rational approaches to improving selectivity in drug designTargeting therapeutics across the blood brain barrier (BBB), prerequisite towards thrombolytic therapy for cerebrovascular disorders-an overview and advancementsPreparation of dibenzo[e,g]isoindol-1-ones via Scholl-type oxidative cyclization reactions.Evaluation of active and passive transport processes in corneas extracted from preserved rabbit eyesOvercoming Chemical, Biological, and Computational Challenges in the Development of Inhibitors Targeting Protein-Protein Interactions.Targeting the neurovascular unit for treatment of neurological disorders.Novel central nervous system drug delivery systems.Small endogenous molecules as moiety to improve targeting of CNS drugs.Can formulation and drug delivery reduce attrition during drug discovery and development-review of feasibility, benefits and challenges.Mechanism of brain targeting by dexibuprofen prodrugs modified with ethanolamine-related structures.Immunohistochemical and functional characterization of peptide, organic cation, neutral and basic amino acid, and monocarboxylate drug transporters in human ocular tissues.LAT-1 activity of meta-substituted phenylalanine and tyrosine analogsProdrug approaches for CNS deliveryTargeting receptor-mediated transport for delivery of biologics across the blood-brain barrier.Various drug delivery approaches to the central nervous system.Novel and emerging strategies in drug delivery for overcoming the blood-brain barrier.Shuttle-mediated drug delivery to the brain.Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery.CNS drug targeting: have we travelled in right path?Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor.Targeting L-type amino acid transporter 1 for anticancer therapy: clinical impact from diagnostics to therapeutics.Amino Acid Promoieties Alter Valproic Acid Pharmacokinetics and Enable Extended Brain Exposure.Cell-specific, activatable, and theranostic prodrug for dual-targeted cancer imaging and therapy.Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.Vectorization of agrochemicals: amino acid carriers are more efficient than sugar carriers to translocate phenylpyrrole conjugates in the Ricinus system.Nanocarriers for brain specific delivery of anti-retro viral drugs: challenges and achievements.Molecular and functional characterization of riboflavin specific transport system in rat brain capillary endothelial cells.LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substratesAmino Acid Carbamates As Prodrugs Of Resveratrol.Direct access to benzo[b]furans through palladium-catalyzed oxidative annulation of phenols and unactivated internal alkynes.Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine.Targeting glioma stem cells through combined BMI1 and EZH2 inhibition.Rational design and structure-activity relationship studies of quercetin-amino acid hybrids targeting the anti-apoptotic protein Bcl-xL.LAT1-mediated prodrug uptake: a way to breach the blood-brain barrier?Mustard-inspired delivery shuttle for enhanced blood-brain barrier penetration and effective drug delivery in glioma therapy.Blood-brain barrier permeability and brain uptake mechanism of kainic acid and dihydrokainic acid.Quantitative insight into the design of compounds recognized by the L-type amino acid transporter 1 (LAT1).Functional Polarity of Microvascular Brain Endothelial Cells Supported by Neurovascular Unit Computational Model of Large Neutral Amino Acid Homeostasis.Insights into the Structure, Function, and Ligand Discovery of the Large Neutral Amino Acid Transporter 1, LAT1.The Human SLC7A5 (LAT1): The Intriguing Histidine/Large Neutral Amino Acid Transporter and Its Relevance to Human Health.
P2860
Q26865357-61D7BAF1-EAD1-4668-A12D-43F537D5E0A8Q30393215-80763CAB-97A9-451B-B3AD-6E0931417F47Q34141705-A8527D24-966D-4ECE-81B7-FB03830E0B7AQ34141933-BF33A082-E97B-4611-B375-304DC2584B70Q34481459-64EA3469-1708-4A5B-A326-D2C7B4A0A022Q34974827-79DD256D-BC91-4C1A-B3BF-D2D155C38FCFQ35064473-6944BDB6-6FE5-4340-BCB5-A3D26F8DEDF6Q36065879-F0A9504A-494B-4A42-9B3A-CC369CFDE75CQ36111924-EAF8A8AD-64C6-4068-B08A-2AF1DD89C451Q36350484-58DFD321-EC99-4783-917E-C6951C3ADDA5Q36573373-55987A0D-A293-4692-A116-A16827E8370EQ36923089-A1AF1D25-8D88-4A90-98A1-D7AD500EF4D8Q37150860-78616723-20E9-4611-B202-30867B5E9C78Q37312010-9C598AD2-3855-40CD-B27D-EE0A4933FAAEQ37657525-333281EB-801A-43C2-8E4E-E3E861DFF4A9Q37855817-87D57255-4227-40D8-876C-B456E3B0CE7AQ37896550-792628A8-2320-43C3-BE23-BDF7823C796EQ37995554-8AB4BDEE-A320-4CCE-BAA9-8364DBE4DC4BQ38127262-773E9D40-A5D4-4A2B-BCA2-5CCA9226694BQ38401892-913D4FF3-AE30-4A88-B3B0-66878564AA9FQ38476583-FD8566E7-5985-4C95-B324-C96F40C73DA6Q38758331-66D6F832-4C5A-4BCB-BE14-5F5469A6B519Q38785651-E608FF6C-0280-407C-84C6-53F964E5110AQ38944343-D432F235-3E54-4439-B1D7-E18E51F2D377Q39103084-734A7E54-A2EC-4E74-8794-0E8811E1B040Q40060003-6E636202-DAC1-44B6-8226-E676069179E4Q41833147-178BF642-782A-4E9B-9FD5-1F51C47D11DAQ42221833-46497F27-A706-4C20-8E00-12484BB114D5Q42592297-55B80115-F7F1-442D-A314-1E97486D9D65Q43932409-95D82A7C-FEBC-4978-AE7E-B92B5D1FF90CQ45951082-2C00C9D8-3FAE-461F-BF68-4E040CC7F584Q47648829-0C081452-81A5-4C9A-8DE8-523EB1DFE3C4Q47810232-529E98BE-67A5-48C2-9DCE-35A0B40B1076Q48148305-EA67AB19-6016-4EF9-9090-02C21F24FC2FQ48229575-C95A2036-0492-4482-9120-2310BAE181F4Q48419626-56A50480-E97A-4B20-BF5C-29490FE90E17Q48554104-759DF93A-99E9-46D9-B061-B48CD613A277Q52338806-55889102-6295-4A29-B9D8-359FE27549FDQ52563214-5D4DE9F3-C921-4702-B3DD-45AEACA2631EQ55514831-77BB4903-AA6B-4516-B7BF-E8D5BB2B79B1
P2860
Large neutral amino acid transporter enables brain drug delivery via prodrugs.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Large neutral amino acid transporter enables brain drug delivery via prodrugs.
@en
Large neutral amino acid transporter enables brain drug delivery via prodrugs.
@nl
type
label
Large neutral amino acid transporter enables brain drug delivery via prodrugs.
@en
Large neutral amino acid transporter enables brain drug delivery via prodrugs.
@nl
prefLabel
Large neutral amino acid transporter enables brain drug delivery via prodrugs.
@en
Large neutral amino acid transporter enables brain drug delivery via prodrugs.
@nl
P2093
P356
P1476
Large neutral amino acid transporter enables brain drug delivery via prodrugs.
@en
P2093
Anne Mannila
Jarmo Ropponen
Jouko Savolainen
Jukka Leppänen
Krista Laine
Mikko Gynther
Tapio Nevalainen
Tomi Järvinen
P304
P356
10.1021/JM701175D
P407
P577
2008-01-25T00:00:00Z